GnIH: Uses, Benefits & Research

What is GnIH?

GnIH (Gonadotropin-Inhibiting Hormone) is a hypothalamic neuropeptide first discovered in 2000 in the Japanese quail. The mammalian ortholog, known as RFRP-3 (RFamide-Related Peptide-3), has been identified in the human hypothalamus through post-mortem tissue analysis. GnIH belongs to the RFamide peptide family and has a molecular weight of approximately 1,000 Da (varying by species).

GnIH acts as a “brake” on the reproductive hormone axis — it inhibits the release of gonadotropins (LH and FSH) from the pituitary gland. This is the opposite function of GnRH (Gonadotropin-Releasing Hormone), which stimulates gonadotropin release.

Critical context: GnIH is not available as a supplement, medication, or commercial research chemical for human use. It exists only as a laboratory research tool in animal and cell culture studies. There are zero human clinical trials and no pharmaceutical development program.

Mechanism of Action

GnIH’s mechanism has been characterized in animal models through the following signaling cascade:

1. Receptor binding: GnIH binds GPR147 (NPFF1R, primary receptor) and GPR74 (NPFF2R, secondary receptor with lower affinity)
2. G-protein coupling: Gai/o protein activation inhibits adenylate cyclase
3. cAMP reduction: Decreased cAMP production reduces calcium mobilization in gonadotrope cells
4. GnRH signal suppression: Inhibition of GnRH signaling to the anterior pituitary
5. Gonadotropin reduction: Decreased LH and FSH secretion
6. Sex steroid reduction: Lower LH/FSH leads to reduced testosterone and estrogen production

Additional proposed effects in animal models include modulation of stress-reproduction interactions (CRF-mediated) and seasonal breeding control in photoperiodic species.

All mechanistic data comes from quail, rat, mouse, and sheep studies. No human binding studies or pharmacodynamic studies have been published.

Clinical Evidence

Human Studies

Human evidence is limited to tissue expression studies:

• Kiyohiko 2009 (PMID: 20027225): Demonstrated RFRP-3 expression in post-mortem human hypothalamic tissue — confirming the protein exists in human brain but not establishing any functional or therapeutic significance
• Ubuka 2014 (PMID: 24789623): Review of GnIH discovery and characterization — describes animal data, no human functional studies
• Zero human RCTs, zero human intervention studies, zero human safety studies

Preclinical

All functional data comes from animal models:

• Dose-dependent LH/FSH suppression in quail, rat, and sheep
• Testosterone suppression in male quail
• Seasonal reproduction control in photoperiodic species
• Stress axis modulation via CRF interaction in rodents
• In vitro inhibition of calcium signaling in sheep pituitary cells

Species differences in reproductive neuroendocrinology significantly limit translation to humans.

Drug Interactions & Contraindications

No formal drug interaction studies exist. Theoretical interactions based on the HPG axis mechanism:

• GnRH agonists/antagonists: Opposing or additive effects on reproductive axis signaling
• Hormone replacement therapy: May counteract exogenous hormone supplementation
• Fertility medications (FSH, LH preparations): Direct mechanistic opposition

GnIH is not available for human use. No dosing, formulation, or administration route has been established.

Safety & Side Effects

No human safety data exists because GnIH has never been administered to any human in any setting. Theoretical concerns based on mechanism include reproductive suppression, endocrine disruption, fertility impairment, and mood/behavioral effects (based on rodent stress data). The compound is not available from any legitimate source.

Honest Bottom Line

GnIH (RFRP-3) is a niche research neuropeptide with limited academic interest based on its role as an inhibitory regulator of the reproductive hormone axis in animals. As of March 2026, there are zero human clinical trials, zero human safety data, and no pharmaceutical development program. The compound is not available from any peptide vendor, compounding pharmacy, or research supplier for human use. No legitimate pathway exists for a patient to obtain or use this compound. Anyone claiming to sell “GnIH” or “RFRP-3” is selling an unverified product. There is nothing actionable here for patients — GnIH exists only in academic neuroscience literature.